Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ABVX.PA
- Price
- 104.00
- Stock movement up
- +2.20 (2.12%)
- Company name
- Abivax SA
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 8.27B
- Ent value
- 7.82B
- Price/Sales
- 1372.31
- Price/Book
- 16.17
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 2.18%
- 1 year return (CAGR)
- 1454.90%
- 3 year return (CAGR)
- 151.95%
- 5 year return (CAGR)
- 39.92%
- 10 year return (CAGR)
- 24.68%
Last updated: 2026-02-13
DIVIDENDS
ABVX.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1372.31 |
| Price to Book | 16.17 |
| EV to Sales | 1297.78 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 77.83M |
| EPS (TTM) | -5.15 |
| FCF per share (TTM) | -3.11 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 6.02M |
| Gross profit (TTM) | 6.02M |
| Operating income (TTM) | -327.04M |
| Net income (TTM) | -401.12M |
| EPS (TTM) | -5.15 |
| EPS (1y forward) | -2.62 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -5429.90% |
| Profit margin (TTM) | -6659.74% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 589.70M |
| Net receivables | 0.00 |
| Total current assets | 619.29M |
| Goodwill | 18.42M |
| Intangible assets | 6.61M |
| Property, plant and equipment | 3.92M |
| Total assets | 652.05M |
| Accounts payable | 14.36M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 78.76M |
| Total liabilities | 140.81M |
| Shareholder's equity | 511.24M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -241.52M |
| Capital expenditures (TTM) | 511.00K |
| Free cash flow (TTM) | -242.03M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -78.46% |
| Return on Assets | -61.52% |
| Return on Invested Capital | -76.10% |
| Cash Return on Invested Capital | -45.92% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 104.60 |
| Daily high | 106.60 |
| Daily low | 102.60 |
| Daily Volume | 77K |
| All-time high | 122.40 |
| 1y analyst estimate | 93.29 |
| Beta | -0.11 |
| EPS (TTM) | -5.15 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 23 Mar 2026 |
Downside potential
Loading...
Downside potential data
| ABVX.PA | S&P500 | |
| Current price drop from All-time high | -15.03% | -0.89% |
| Highest price drop | -87.30% | -56.47% |
| Date of highest drop | 9 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -48.91% | -10.86% |
| Avg time to new high | 62 days | 12 days |
| Max time to new high | 1166 days | 1805 days |
COMPANY DETAILS
Marketcap
8.27B
Marketcap category
Mid-cap
Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Employees
67
Website
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Could these two companies be biotech giants in the making?
February 11, 2026
ABIVAX Société Anonyme recently reported that its lead drug candidate, obefazimod, delivered positive Phase 3 results in ulcerative colitis, meeting key secondary endpoints with a clean safety profile...
February 4, 2026
We came across a bullish thesis on ABIVAX Société Anonyme on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on ABVX. ABIVAX ...
February 3, 2026
ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the 11 Best Performing Stocks in the Last 12 Months. For the past couple of months, speculation has arisen that Eli Lilly, an American multinational phar...
February 2, 2026
The choice between the two might come down to each investor's goals and risk tolerance.
January 30, 2026
Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 0.2% and th
January 20, 2026
And the share price appreciation could happen pretty soon.
January 19, 2026
If you are wondering whether ABIVAX Société Anonyme is priced attractively at its current level, the key question is how the market is weighing its potential against the risks. The share price last cl...
January 17, 2026
Shifting regulatory policies and evolving US drug pricing dynamics have created a favourable environment for deals.
January 13, 2026
↘️ American Express (AXP), Bank of America (BAC): Shares of the biggest U.S. banks and credit-card companies dropped after President Trump called for credit-card interest rates to be capped. Shares in...
January 12, 2026
Next page